Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer. NICE technology appraisal guidance 1041
National Institute for Health and Care Excellence (NICE)
Record ID 32018013908
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta1041
Year Published:
2025
URL for published report:
https://www.nice.org.uk/guidance/ta1041
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Carboplatin
- Etoposide
- Cisplatin
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
3rd floor, 3 Piccadilly Place, Manchester, M1 3BN
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.